- Home
- FBRX
as of 01-22-2026 3:43pm EST
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | DALLAS |
| Market Cap: | 367.4M | IPO Year: | N/A |
| Target Price: | $67.00 | AVG Volume (30 days): | 176.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.90 - $35.46 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered FBRX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Forte Biosciences Inc. (FBRX)
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$26.33
Shares
9,680
Total Value
$254,832.78
Owned After
41,520
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Riley Antony A | FBRX | CHIEF FINANCIAL OFFICER | Dec 30, 2025 | Buy | $26.33 | 9,680 | $254,832.78 | 41,520 |
Compare FBRX vs Leading Stocks
See how FBRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "FBRX Forte Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.